Meeting
2014 ASCO Annual Meeting
Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Children’s Oncology Group (COG) AALL0932.
Authors
Nina S. Kadan-Lottick
Yale School of Medicine, Smilow Cancer Center, New Haven, CT
Nina S. Kadan-Lottick , Xiaomin Lu , Marilyn Hockenberry , Moira K. Whitley , Stephen Hunger , Meenakshi Devidas , Naomi Joan Winick , Reuven J. Schore , Anne L. Angiolillo , Kirsten K. Ness
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT01190930
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7056)
DOI
10.1200/jco.2014.32.15_suppl.7056
Abstract #
7056
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children’s Oncology Group (COG) trials.
First Author: Kelly W. Maloney
Poster
2023 ASCO Annual Meeting
Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.
First Author: Lyn M. Balsamo
Poster
2018 ASCO Annual Meeting
Open-label, dose-escalation, phase 1 study of venetoclax in combination with navitoclax and chemotherapy in patients with relapsed acute lymphoblastic leukemia.
First Author: Thomas Alexander
Poster
2016 ASCO Annual Meeting
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, doxorubicin, and PEG-asparaginase (VPLD).
First Author: Julio C. Barredo